🧬 Sun Pharma to Invest $100 Million in FY26: Major Boost for Speciality Drug Business
Mumbai, June 1, 2025 – Leading pharmaceutical giant Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) has announced a substantial $100 million investment for FY26 to accelerate the commercialisation of innovative speciality medicines, including Unloxcyt and Leqselvi.
According to Chairman and Managing Director Dilip Shanghvi, this capital outlay will strengthen Sun Pharma’s global specialty drug pipeline and reinforce its leadership in the pharmaceutical market.
“We are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products,” Shanghvi said during a post-earnings call.
💊 What’s Driving the Investment?
The funds will support:
Launch of Unloxcyt: Recently approved for metastatic cutaneous squamous cell carcinoma
Commercialisation of Leqselvi: A promising treatment for severe alopecia areata
Strategic reassessment and potential partnerships for MM-II, a product targeting osteoarthritis pain
Initiation of clinical trials for GL0034, focused on type 2 diabetes
Shanghvi added that Sun Pharma continues to believe in MM-II's potential and is currently seeking commercial partners in select markets.
📉 Sun Pharma’s Global Strategy and Acquisition Moves
Sun Pharma is in the process of acquiring Checkpoint Therapeutics, a US-based oncology company. Notably, Checkpoint’s Unloxcyt has received FDA approval, which Sun Pharma will scale using its commercial network.
This move highlights the company’s aggressive push into the US speciality market, even as US formulation sales saw a slight decline of 2.5% YoY to $464 million in Q4 FY25.
📈 FY25 Results: Sunpharma Share Price Backed by Strong Fundamentals
| 📊 Metric | FY25 Figures |
|---|---|
| Total Revenue | ₹5,20,410 million (~$6.24 billion) |
| India Formulation Sales | ₹4,213 crore (↑13.6%) |
| Global Speciality Sales | $1,216 million (↑17.1%) |
| R&D Expenses (Q4) | ₹816.6 crore |
| EBITDA Growth | 22.4% YoY |
| Revenue Growth (Q4) | 8.1% YoY |
Sun Pharma expects mid-to-high single-digit growth in FY26, with R&D spending projected between 6% and 8% of revenue.
📈 Sun Pharma Share Price Trends (2024–2025)
Sunpharma share price saw consistent bullish momentum in 2024.
Temporary correction in early 2025 due to US market softness.
Strong fundamentals and FY26 growth outlook have rekindled interest.
| Period | Share Price Movement |
|---|---|
| Jan 2024 | ₹1,040 |
| Oct 2024 | ₹1,212 |
| Mar 2025 | ₹1,134 |
| Today (June 2025) | ₹1,165+ (approx)* |
*Real-time data may vary; check NSE/BSE for latest.
📊 NSE: SUNPHARMA Stock Performance and Market Sentiment
Sun Pharma share price today is a hot topic among investors, as the company’s expansion plan fuels interest. Investors tracking the sun pharma stock price on NSE and BSE have noted:
Sunpharma share price target updates are now more bullish
Sun pharmaceutical industries ltd share price is under active observation by analysts
Sun pharma market cap continues to grow as revenue expands
Join WhatsApp Group
